However, the mechanistic effect of RAD21 or NIPBL in cancers, including NSCLC, is largely unclear, and further studies are needed to determine whether RAD21 or NIPBL could be an indicator for the use of PI3K inhibitors in NSCLC. The gene discussed is NIPBL; the disease is cancer.